



for immediate release

Edmonton Company Announces Clinical Study for Treatment of Osteoporosis

On June 22, 2011, Edmonton-based **SinoVeda Canada Inc.** will hold a media event announcing its clinical study for the research & development of an innovative osteoporosis program beginning with its product *Pearlium*.

SinoVeda's patent pending PPT® technology and its multiple-ingredient, multiple-target (MIMT™) method are safer than and as effective as pharmaceuticals, with fewer side effects in the areas of bone, cardiovascular and mental health. The proprietary products are unique in that the active and absorbable ingredients are accurately quantified and standardized, an industry first for non-prescription supplements.

Please join us to learn more about this local success story and its cutting-edge clinical trial.

WHO: SinoVeda Canada Inc.
WHAT: Media Event
WHEN: Wednesday, June 22, 2011
10:30 a.m.
WHERE: Advanced Technology Centre
9650-20 Avenue NW, Edmonton
WHY: To announce the first of a series of clinical trials SinoVeda's osteoporosis program
HOW: Interviews and photograph opportunities available following the presentation.
Refreshments served after announcement.

SinoVeda's goal is to become a top global developer and supplier of branded, patented, clinically-proven, specialty nutritional ingredients for food, dietary supplements, over-the-counter and prescription products. The vision of its founders is to authenticate the effectiveness of health products and medicines natural and botanical resources for some of the most commonly suffered health conditions.

SinoVeda Canada Inc. is currently partnered with the Cross Cancer Institute, University of Alberta Drug Development Center, and School of Botanical Sciences at the Chinese University in Hong Kong.

For additional information please contact:

Tim Hanas
Media Contact
p. 780-721-6704
thanas@sinoveda.com